相關(guān)文章 / article
簡要描述：Chiralix 廣州鴻程代理 基始終致力于面向生命科學(xué)領(lǐng)域，從事科研機(jī)構(gòu)及生產(chǎn)企業(yè)所需的各類原料、試劑、耗材、儀器等的專業(yè)進(jìn)出口公司。專門從事以抗*Beckman A63881的磁珠 現(xiàn)貨，moltox 11-101.5等現(xiàn)貨， 706020/706025現(xiàn)貨，Megazyme的大部分現(xiàn)貨
產(chǎn)品型號：廠商性質(zhì)：經(jīng)銷商更新時間：2024-06-18訪 問 量：653| 品牌 | 其他品牌 | 適用領(lǐng)域 | 科研 |
|---|---|---|---|
| 產(chǎn)地 | 進(jìn)口 | 加工定制 | 是 |
廣州鴻程生物有限公司一家專注于生命科學(xué)的科技企業(yè)，由在國內(nèi)科研試劑領(lǐng)域有著豐富從業(yè)經(jīng)驗(yàn)的技術(shù)團(tuán)隊和管理團(tuán)隊組建而成，專營進(jìn)口生物試劑，科學(xué)儀器，實(shí)驗(yàn)消耗品等。公司將不斷把上優(yōu)質(zhì)的產(chǎn)品引入國內(nèi)市場，滿足客戶的需求，公司也將緊跟生命科學(xué)的發(fā)展，為廣大科研工作者探索生命科學(xué)的奧秘奉獻(xiàn)綿薄之力.專門從事以抗*Beckman A63881的磁珠 現(xiàn)貨，moltox 11-101.5等現(xiàn)貨，transgenomic 706020/706025現(xiàn)貨
Chiralix 廣州鴻程代理
Chiralix 廣州鴻程代理
Chiralix是一家專業(yè)從事手性有機(jī)分子合成和供應(yīng)的公司，我們致力于制藥公司及生命科學(xué)研究領(lǐng)域的實(shí)驗(yàn)室研究用*手性分子的生產(chǎn)和研發(fā)。我們集的有機(jī)分子合成、過渡金屬催化、生物催化技術(shù)于一身，具備靈活與高效的多種手性分子合成工藝，如基團(tuán)的氨基酸，疊氮酸，氨基醇及多種肽段模塊。除了提供大量的手性分子成品，我們還提供優(yōu)質(zhì)的研發(fā)服務(wù)，如復(fù)雜有機(jī)分子的合成等。
公司主要產(chǎn)品：
1、氨基酸類：包括各種以氨基酸為骨架的手性衍生物。
貨號 | 品名 | 化學(xué)名 | CAS號 | 分子量 | 分子式 | Synonyms | 純度 | 包裝 | 價格 |
CX90418-1G | L-allysine ethylene acetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoic acid | 215054-80-1 | 189.21 | C8 H15 N O4 | H-Aea-OH | 99% | 1 G | 6200 |
CX90418-2G | L-allysine ethylene acetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoic acid | 215054-80-1 | 189.21 | C8 H15 N O4 | H-Aea-OH | 99% | 2 G | 10600 |
CX90418-5G | L-allysine ethylene acetal | (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoic acid | 215054-80-1 | 189.21 | C8 H15 N O4 | H-Aea-OH | 99% | 5 G | 19900 |
CX60325-200MG | D-homopropargylglycine | (R)-2-aminohex-5-ynoic acid | 211054-02-3 | 127.14 | C6 H9 N O2 | H-D-Hpg-OH | >98% | 200 MG | 4800 |
CX60325-500MG | D-homopropargylglycine | (R)-2-aminohex-5-ynoic acid | 211054-02-3 | 127.14 | C6 H9 N O2 | H-D-Hpg-OH | >98% | 500 MG | 9800 |
CX60325-1G | D-homopropargylglycine | (R)-2-aminohex-5-ynoic acid | 211054-02-3 | 127.14 | C6 H9 N O2 | H-D-Hpg-OH | >98% | 1 G | 16000 |
CX80065-500MG | Fmoc-L-homopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoic acid | 942518-21-0 | 349.38 | C21 H19 N O4 | Fmoc-Hpg-OH | >97% | 500 MG | 11200 |
CX80065-1G | Fmoc-L-homopropargylglycine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)hex-5-ynoic acid | 942518-21-0 | 349.38 | C21 H19 N O4 | Fmoc-Hpg-OH | >97% | 1 G | 18400 |
CX90138-200MG | L-homopropargylglycine | (S)-2-aminohex-5-ynoic acid | 98891-36-2 | 127.14 | C6 H9 N O2 | H-Hpg-OH | >98% | 200 MG | 4800 |
CX90138-500MG | L-homopropargylglycine | (S)-2-aminohex-5-ynoic acid | 98891-36-2 | 127.14 | C6 H9 N O2 | H-Hpg-OH | >98% | 500 MG | 9800 |
CX90138-1G | L-homopropargylglycine | (S)-2-aminohex-5-ynoic acid | 98891-36-2 | 127.14 | C6 H9 N O2 | H-Hpg-OH | >98% | 1 G | 16000 |
CX56292-500MG | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylic acid | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylic acid | 108646-25-9 | 156.14 | C7 H8 O4 | >97% | 500 MG | 6000 | |
CX56292-1G | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylic acid | (3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylic acid | 108646-25-9 | 156.14 | C7 H8 O4 | >97% | 1 G | 9800 | |
CX24022-500MG | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylic acid | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylic acid | 38127-17-2 | 155.15 | C7 H9 N O3 | >98% | 500 MG | 6000 | |
CX24022-1G | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylic acid | (5S,6S)-6-amino-5-hydroxycyclohexa-1,3-dienecarboxylic acid | 38127-17-2 | 155.15 | C7 H9 N O3 | >98% | 1 G | 9800 | |
CX41399-1G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoic acid | 40856-44-8 | 165.19 | C9 H11 N O2 | 99% | 1 G | 2200 | |
CX41399-2G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoic acid | 40856-44-8 | 165.19 | C9 H11 N O2 | 99% | 2 G | 3800 | |
CX41399-5G | (S)-beta3-phenylalanine | (S)-3-amino-3-phenylpropanoic acid | 40856-44-8 | 165.19 | C9 H11 N O2 | 99% | 5 G | 7200 | |
CX64691-1G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyric acid | 26782-71-8 | 131.17 | C6 H13 N O2 | H-D-tert-Leu-OH | 99% | 1 G | 2200 |
CX64691-2G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyric acid | 26782-71-8 | 131.17 | C6 H13 N O2 | H-D-tert-Leu-OH | 99% | 2 G | 3800 |
CX64691-5G | D-tert-leucine | (R)-2-amino-3,3-dimethylbutyric acid | 26782-71-8 | 131.17 | C6 H13 N O2 | H-D-tert-Leu-OH | 99% | 5 G | 7200 |
CX97471-500MG | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoic acid | 13398-26-0 | 165.19 | C9 H11 N O2 | (S)-H-Mpg-OH | >98% | 500 MG | 5200 |
CX97471-1G | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoic acid | 13398-26-0 | 165.19 | C9 H11 N O2 | (S)-H-Mpg-OH | >98% | 1 G | 9000 |
CX97471-2G | (S)-alpha-methyl-phenylglycine | (S)-2-amino-2-phenylpropanoic acid | 13398-26-0 | 165.19 | C9 H11 N O2 | (S)-H-Mpg-OH | >98% | 2 G | 14800 |
CX58692-1G | (S)-allylglycinol hydrochloride | (S)-2-aminopent-4-en-1-ol hydrochloride | 926660-03-9 | 137.61 | C5 H12 Cl N O | >98% | 1 G | 7400 | |
CX58692-2G | (S)-allylglycinol hydrochloride | (S)-2-aminopent-4-en-1-ol hydrochloride | 926660-03-9 | 137.61 | C5 H12 Cl N O | >98% | 2 G | 12800 | |
CX40529-1G | (S)-propargylglycinol hydrochloride | (S)-2-aminopent-4-yn-1-ol hydrochloride | Not available | 135.59 | C5 H10 Cl N O | >98% | 1 G | 8200 | |
CX40529-2G | (S)-propargylglycinol hydrochloride | (S)-2-aminopent-4-yn-1-ol hydrochloride | Not available | 135.59 | C5 H10 Cl N O | >98% | 2 G | 14000 | |
CX80916-500MG | bis(N-Cbz)-2-deoxystreptamine | benzyl 4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 6216-32-6 | 430.45 | C22 H26 N2 O7 | bis-Z-2-DOS | >95% | 500 MG | 6200 |
CX80916-1G | bis(N-Cbz)-2-deoxystreptamine | benzyl 4,5,6-trihydroxycyclohexane-1,3-diyldicarbamate | 6216-32-6 | 430.45 | C22 H26 N2 O7 | bis-Z-2-DOS | >95% | 1 G | 10800 |
CX93851-100MG | (2S,5R)-5-hydroxypipecolic acid hydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylic acid hydrochloride | 824943-40-0 | 181.62 | C6 H12 Cl N O3 | >98% | 100 MG | 3800 | |
CX93851-500MG | (2S,5R)-5-hydroxypipecolic acid hydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylic acid hydrochloride | 824943-40-0 | 181.62 | C6 H12 Cl N O3 | >98% | 500 MG | 12600 | |
CX93851-1G | (2S,5R)-5-hydroxypipecolic acid hydrochloride | (2S,5R)-5-hydroxypiperidine-2-carboxylic acid hydrochloride | 824943-40-0 | 181.62 | C6 H12 Cl N O3 | >98% | 1 G | 19600 | |
CX19922-1G | (S)-beta3-phenylalanine methyl ester hydrochloride | (S)-methyl 3-amino-3-phenylpropanoate hydrochloride | 144494-72-4 | 215.68 | C10 H14 Cl N O2 | >98% | 1 G | 3000 | |
CX19922-2G | (S)-beta3-phenylalanine methyl ester hydrochloride | (S)-methyl 3-amino-3-phenylpropanoate hydrochloride | 144494-72-4 | 215.68 | C10 H14 Cl N O2 | >98% | 2 G | 5200 | |
CX19922-5G | (S)-beta3-phenylalanine methyl ester hydrochloride | (S)-methyl 3-amino-3-phenylpropanoate hydrochloride | 144494-72-4 | 215.68 | C10 H14 Cl N O2 | >98% | 5 G | 9800 | |
CX62577-10MG | 6,8a-diepi-castanospermine | (1S,6R,7R,8R,8aS)-octahydroindolizine-1,6,7,8-tetraol | 106798-21-0 | 189.21 | C8 H15 N O4 | >98% | 10 MG | 3600 | |
CX62577-50MG | 6,8a-diepi-castanospermine | (1S,6R,7R,8R,8aS)-octahydroindolizine-1,6,7,8-tetraol | 106798-21-0 | 189.21 | C8 H15 N O4 | >98% | 50 MG | 11800 | |
CX25404-1G | Fmoc-L-azidoornithine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-azidopentanoic acid | 1097192-04-5 | 380.40 | C20 H20 N4 O4 | Fmoc-Orn(N2)-OH | >98% | 1 G | 3400 |
CX25404-5G | Fmoc-L-azidoornithine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-azidopentanoic acid | 1097192-04-5 | 380.40 | C20 H20 N4 O4 | Fmoc-Orn(N2)-OH | >98% | 5 G | 12000 |
CX23880-5MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17 H14 O5 | >98% | 5 MG | 5000 | |
CX23880-20MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17 H14 O5 | >98% | 20 MG | 15000 | |
CX23880-100MG | rac-GR24 | (3aR*,8bS*,E)-3-(((R*)-4-methyl-5-oxo-2,5-dihydrofuran-2-yloxy)methylene)-3,3a,4,8b-tetrahydro-2H-inde,2-b]furan-2-one | 76974-79-3 | 298.29 | C17 H14 O5 | >98% | 100 MG | 35000 | |
CX38605-1G | Fmoc-L-allysine ethylene acetal | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(1,3-dioxolan-2-yl)pentanoic acid | Not available | 411.45 | C23 H25 N O6 | Fmoc-Aea-OH | >97% | 1 G | 7200 |
CX38605-2G | Fmoc-L-allysine ethylene acetal | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(1,3-dioxolan-2-yl)pentanoic acid | Not available | 411.45 | C23 H25 N O6 | Fmoc-Aea-OH | >97% | 2 G | 12400 |
CX59650-1G | Fmoc-L-azidohomoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-azidobutanoic acid | 942518-20-9 | 366.37 | C19 H18 N4 O4 | Fmoc-Azh-OH | >98% | 1 G | 3400 |
CX59650-5G | Fmoc-L-azidohomoalanine | (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-azidobutanoic acid | 942518-20-9 | 366.37 | C19 H18 N4 O4 | Fmoc-Azh-OH | >98% | 5 G | 12000 |
CX94894-200MG | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoic acid | 835627-45-7 | 141.17 | C7 H11 N O2 | H-Bpg-OH | >98% | 200 MG | 4400 |
CX94894-500MG | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoic acid | 835627-45-7 | 141.17 | C7 H11 N O2 | H-Bpg-OH | >98% | 500 MG | 9000 |
CX94894-1G | L-bishomopropargylglycine | (S)-2-aminohept-6-ynoic acid | 835627-45-7 | 141.17 | C7 H11 N O2 | H-Bpg-OH | >98% | 1 G | 14600 |
CX13745-1G | (R)-propargylglycinol hydrochloride | (R)-2-aminopent-4-yn-1-ol hydrochloride | Not available | 135.59 | C5 H10 Cl N O | >98% | 1 G | 8200 | |
CX13745-2G | (R)-propargylglycinol hydrochloride | (R)-2-aminopent-4-yn-1-ol hydrochloride | Not available | 135.59 | C5 H10 Cl N O | >98% | 2 G | 14000 | |
CX78500-1G | (R)-allylglycinol hydrochloride | (R)-2-aminopent-4-en-1-ol hydrochloride | 926660-30-2 | 137.61 | C5 H12 Cl N O | >98% | 1 G | 7400 |
